Patents by Inventor Hamideh Zarrinmayeh

Hamideh Zarrinmayeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200123104
    Abstract: Disclosed are P2X7 receptor ligands having the formula (I): in which R=—(CH2)n—(O—CH2CH2)m—Ol—(CH2)p—X, l=0-1, m=0-6, n=2-3, p=0-2, and X=Br, Cl, F or 18F. In illustrative embodiments, R=—(CH2)n, and n=2-3. The receptor ligands are used in methods related to conditions related to the P2X7 receptor. The non-radioligands are useful for modulating inflammation conditions associated with the P2X7 receptor. The radioligands, containing 18F, are useful for as radiotracers in imaging processes, and thus for the detection and evaluation of inflammation and therapies. Also provided are processes for preparation of these P2X7 receptor ligands.
    Type: Application
    Filed: June 28, 2018
    Publication date: April 23, 2020
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Hamideh Zarrinmayeh, Mark Alan Green
  • Patent number: 7642361
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: January 5, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano, Maria Carmen Fernandez, William Joseph Hornback, Alma Maria Jimenez-Aguado, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 7625932
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: December 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang, Paul Leslie Ornstein, Michelle Lee Thompson, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Ana Maria Castano Mansanet, Larry Gene Huffman, William David Miller
  • Publication number: 20070105852
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Application
    Filed: January 5, 2005
    Publication date: May 10, 2007
    Inventors: Ana Castano Mansanet, Esteban Dominguez-Manzanares, Ana Escribano, Maria Fernandez, William Hornback, Alma Jimenez-Aguado, Eric Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Zimmerman
  • Publication number: 20070066573
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Application
    Filed: September 27, 2004
    Publication date: March 22, 2007
    Inventors: Pamela Albaugh, Esteban Dominguez-Manzanares, Jian Hong, William Hornback, Delu Jiang, Paul Ornstein, Michelle Thompson, Eric Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Zimmerman, Ana Castano Mansanet, Larry Huffman, William Miller
  • Patent number: 7135487
    Abstract: The present invention relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: November 14, 2006
    Assignee: Eli Lilly and Company
    Inventors: Macklin B Arnold, Stephen R Baker, Thomas J Bleisch, Buddy E Cantrell, Ana M Escribano, Ken Matsumoto, Tracey E McKennon, Paul L Ornstein, Richard L Simon, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M Zimmerman
  • Patent number: 7034045
    Abstract: The present invention provides certain monofluoroalkyl derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: April 25, 2006
    Assignee: Eli Lilly and Company
    Inventors: David Michael Bender, Buddy Eugene Cantrell, Andrew Hendley Fray, Winton Dennis Jones, William David Miller, David Mitchell, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20060030599
    Abstract: Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula R1-L-NHSO2R2??I in which R1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C) chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)
    Type: Application
    Filed: May 29, 2003
    Publication date: February 9, 2006
    Inventors: Macklin Arnold, Stephen Baker, Thomas Bleisch, Buddy Cantrell, Ana Escribano, Ken Matsumoto, Tracey Mckennon, Paul Ornstein, Richard Simon, Edward Smith, Hamideh Zarrinmayeh, Dennis Zimmerman
  • Patent number: 6911476
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: June 28, 2005
    Assignee: Eli Lilly and Company
    Inventors: Joshua Zwick Davison, Winton Dennis Jones, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6900353
    Abstract: The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: May 31, 2005
    Assignee: Eli Lilly and Company
    Inventors: Buddy Eugene Cantrell, Winton Dennis Jones, Jr., Timothy Alan Shepherd, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20040157842
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Application
    Filed: February 6, 2004
    Publication date: August 12, 2004
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20040147612
    Abstract: The present invention provides certain sulfonamide derivatives of formula (I) (in which the variables are as defined in the claims) useful for potentiating glutamate receptor function in a patient and therefore useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: November 24, 2003
    Publication date: July 29, 2004
    Inventors: Joshua Zwick Davison, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6720357
    Abstract: The present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: October 17, 2002
    Date of Patent: April 13, 2004
    Assignee: Eli Lilly and Company
    Inventors: Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20040067984
    Abstract: The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: March 11, 2003
    Publication date: April 8, 2004
    Inventors: Buddy Eugene Cantrell, Winton Dennis Jones, Timothy Alan Shepherd, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6713516
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20040054009
    Abstract: The present invention provides (bis) sulfonamide derivatives of formula (I) useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: November 6, 2002
    Publication date: March 18, 2004
    Inventors: James Allen Knobelsdorf, Hamideh Zarrinmayeh
  • Patent number: 6703425
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: March 9, 2004
    Assignee: Eli Lilly and Company
    Inventors: James Allen Knobelsdorf, Timothy Alan Shepherd, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6693137
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 17, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Buddy Eugene Cantrell, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Edward C. R. Smith, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20030233015
    Abstract: The present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Application
    Filed: October 17, 2002
    Publication date: December 18, 2003
    Inventors: James Abraham Aikins, Andrew Hendley Fray, William David Miller, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20030229102
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders 1
    Type: Application
    Filed: November 15, 2002
    Publication date: December 11, 2003
    Inventors: James Allen Knobelsdorf, Timothy Alan Shepherd, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman